Abstract

BackgroundSirolimus-based regimens have recently been introduced as nephron-sparing strategies to avoid the calcineurin inhibitors–induced nephrotoxicity. MethodsTo investigate the different effects of these 2 immunosuppressants on CD4+CD25hiFoxP3+ regulatory T cells (Tregs) and the newly defined subsets of FoxP3+ T cells, including CD45RA−FoxP3lo cytokine-secreting T cells (csT cells), CD45RA−FoxP3hi activated Treg (aTregs), and CD45RA+FoxP3+ resting Treg (rTregs), 52 cases of renal transplant recipients who have received a maintenance immunosuppressive regimen comprised either cyclosporine (n = 34) or sirolimus (n = 18) were collected and proportion of Tregs and each subset of FoxP3+ T cells in peripheral blood was detected by flowcytometry. ResultsSirolimus significantly prompted the proportion of Tregs (5.92 ± 0.40 vs 2.19 ± 0.18; P < .001) and both of the CD45RA-negative subsets, including csT cells (4.92 ± 0.50 vs 1.83 ± 0.18; P < .001) and aTregs (1.04 ± 0.15 vs 0.23 ± 0.05; P < .05) when compared with cyclosporine. However, the rTregs were not remarkably affected (0.36 ± 0.09 vs 0.79 ± 0.28; P = .063). ConclusionSirolimus plays its immune regulatory role in renal transplantation partly by increasing the proportion of Tregs. However, the increasing of both pro- and anti-inflammatory subsets of FoxP3+ T cells also indicates the potential compromising of the effects of sirolimus on immune regulation.

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.